WallStreetZenWallStreetZen

NASDAQ: KYTX
Kyverna Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for KYTX

Based on 2 analysts offering 12 month price targets for Kyverna Therapeutics Inc.
Min Forecast
$39.00+200%
Avg Forecast
$39.50+203.85%
Max Forecast
$40.00+207.69%

Should I buy or sell KYTX stock?

Based on 2 analysts offering ratings for Kyverna Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KYTX stock forecasts and price targets.

KYTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-04
lockedlocked$00.00+00.00%2024-03-04

1 of 1

Forecast return on equity

Is KYTX forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is KYTX forecast to generate an efficient return on assets?
Insufficient data to display

KYTX revenue forecast

What is KYTX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$15.0M
Avg 2 year Forecast
$20.0M
Avg 3 year Forecast
$25.0M

KYTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KYTX$13.00$39.50+203.85%Strong Buy
ENGN$12.86$34.40+167.50%Strong Buy
IGMS$9.55$15.25+59.69%Buy
SVRA$4.08$10.25+151.23%Strong Buy
CDMO$8.74$12.50+43.02%Strong Buy

Kyverna Therapeutics Stock Forecast FAQ

Is Kyverna Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: KYTX) stock is to Strong Buy KYTX stock.

Out of 2 analysts, 2 (100%) are recommending KYTX as a Strong Buy, 0 (0%) are recommending KYTX as a Buy, 0 (0%) are recommending KYTX as a Hold, 0 (0%) are recommending KYTX as a Sell, and 0 (0%) are recommending KYTX as a Strong Sell.

If you're new to stock investing, here's how to buy Kyverna Therapeutics stock.

What is KYTX's revenue growth forecast for 2024-2026?

(NASDAQ: KYTX) Kyverna Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.65%.

Kyverna Therapeutics's revenue in 2024 is N/A.On average, 1 Wall Street analysts forecast KYTX's revenue for 2024 to be $646,728,660, with the lowest KYTX revenue forecast at $646,728,660, and the highest KYTX revenue forecast at $646,728,660. On average, 1 Wall Street analysts forecast KYTX's revenue for 2025 to be $862,304,880, with the lowest KYTX revenue forecast at $862,304,880, and the highest KYTX revenue forecast at $862,304,880.

In 2026, KYTX is forecast to generate $1,077,881,100 in revenue, with the lowest revenue forecast at $1,077,881,100 and the highest revenue forecast at $1,077,881,100.

What is KYTX's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: KYTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 4.89%.

What is KYTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year KYTX price target, the average KYTX price target is $39.50, with the highest KYTX stock price forecast at $40.00 and the lowest KYTX stock price forecast at $39.00.

On average, Wall Street analysts predict that Kyverna Therapeutics's share price could reach $39.50 by Mar 4, 2025. The average Kyverna Therapeutics stock price prediction forecasts a potential upside of 203.85% from the current KYTX share price of $13.00.

What is KYTX's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: KYTX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.